Key Takeaways
- Telum Therapeutics raised $19.3M (Series A) from AMR Action Fund, Inveready, Invivo Partners, CDTI, Clave Capital, Sodena.
- Sector: Biotechnology & Life Sciences, Healthcare, Healthtech & Medtech.
- Geography: Spain.
Analysis
- Telum Therapeutics has successfully closed a Series A funding round of €18 million.
- The round was led by AMR Action Fund, with participation from Inveready and existing investors.
- The funds will be used to advance Telum's lead program targeting bacterial pneumonia caused by Acinetobacter baumannii.
- This funding is expected to support the lead candidate through Phase I clinical development.
- The investment highlights the growing focus on combating antimicrobial resistance (AMR).